Index of drugs

Duodenal and stomach ulcer disease. Treatment of reflux oesophagitis. Prevention of reflux oesophagitis. eradicationHelicobacter pylori in combination with appropriate antibiotic therapy, in the treatment of peptic ulcer diseaseH. pylori. Treatment of benign gastric and duodenal ulceration associated with the treatment of non-steroidal anti-inflammatory drugs (NSAIDs) in patients requiring continuous NSAID treatment. Prevention of gastric and duodenal ulcers accompanying the treatment of NSAIDs in patients at risk who require constant treatment. Gastroesophageal reflux disease with symptoms. Zollinger and Ellison syndrome.

1 capsule contains 15 mg or 30 mg of lansoprazole. The drug contains sucrose.

Proton pump inhibitor. It inhibits the secretion of gastric juice in the parietal cells of the stomach as a result of blocking H activity⁺/ K⁺-ATP-azy (the so-called proton pump). The action of the drug is reversible, depends on the dose and leads to inhibition of both basal and stimulated secretion. A single oral administration of 30 mg of lansoprazole inhibits gastric excretion of gastric acid by about 80% stimulated by pentagastrin. After 7 days of regular use, production of gastric acid decreases by approx. 90%. Lansoprazole is rapidly absorbed from the gastrointestinal tract, reaching C_max within 1.5-2 h. Bioavailability is 80-90%, food slows absorption and reduces the bioavailability of the drug. It is 97% bound to plasma proteins. It is metabolised in the liver, mainly by the CYP2C19 isoenzyme and partly by the CYP3A4 isoenzyme. T_0,5 is 1-2 hours, in the elderly it increases by about 50-100%. Excreted in 1/3 in the form of metabolites in the urine, the remainder in the faeces. Exposure to lansoprazole increases 2-fold in patients with mild hepatic impairment and significantly more pronounced in patients with moderate or severe hepatic impairment.

Hypersensitivity to lansoprazole or other ingredients of the preparation. Do not use in patients who are being treated concomitantly with atazanavir.

It is not recommended to use the drug in children, due to the limited amount of clinical data. Caution should be exercised in patients with moderate or severe hepatic impairment. Treatment with lansoprazole may cause a slight increase in the risk of gastrointestinal infections caused by bacteria such asSalmonella andCampylobacter. Patients with gastric and duodenal ulcer disease should be aware of the possibility of infectionH. pylori as a causative agent of the disease. If the maintenance treatment lasts for more than a year, regular monitoring with the assessment of possible benefits and risks for the patient is recommended. If severe and / or persistent diarrhea occurs, discontinue use. Prevention of peptic ulcers in patients requiring long-term NSAID treatment should only be used in risk groups (eg gastrointestinal bleeding, perforation or ulcer history, advanced age, concomitant use of drugs known to increase the risk of adverse events on the upper gastrointestinal tract, coexistence of severe diseases or long-term use of NSAIDs at the highest recommended doses). Due to the increased risk of bone fractures during treatment, patients with risk factors for osteoporosis should take appropriate doses of vit according to the current clinical guidelines. D and calcium. For patients who are prescribed for long-term treatment or who use proton pump inhibitors concomitantly with Digoxin or preparations that may cause hypomagnesaemia (eg diuretics), Magnesium measurement should be considered prior to initiating treatment with proton pump inhibitors and periodically during treatment. The product contains sucrose - the preparation should not be used in patients with fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase deficiency.

The use of the drug during pregnancy is not recommended (no studies).During breastfeeding, use only if the expected benefits to the mother outweigh the potential danger to the baby being fed.

Common: headache, dizziness; nausea, diarrhea, stomach ache, constipation, vomiting, bloating with the passing of winds, dry mouth or throat; increase in liver enzymes; urticaria, pruritus, rash; fatigue. Uncommon: thrombocytopenia, eosinophilia, leukopenia; depression; arthralgia, muscle pain, hip fracture, carpal or spinal bones; swelling. Rare: anemia; insomnia, hallucinations, confusion; anxiety, dizziness with impaired balance, paresthesia, drowsiness, muscular tremors; blurred vision; tongue inflammation, esophageal candidiasis, pancreatitis, dysgeusia, hepatitis, jaundice; ecchymosis, purpura, loss of hair, erythema multiforme, hypersensitivity to light; interstitial nephritis, gynecomastia; fever, increased sweating, angioneurotic edema, anorexia, impotence. Very rare: agranulocytosis, pancytopenia, colitis, oral mucositis; Stevens-Johnson syndrome, toxic epidermal necrolysis, anaphylactic shock, increased cholesterol and triglyceride levels, hyponatremia. Frequency unknown: hypomagnesemia.

Orally. Adults. Duodenal ulcer: 30 mg once daily for 2 weeks, if necessary continue for another 2 weeks. Peptic ulcer: 30 mg once daily for 4 weeks, if necessary continue for another 4 weeks Reflux oesophagitis: 30 mg once a day for 4 weeks, if necessary continue for another 4 weeks Preventing reflux oesophagitis: 15 mg once a day, if necessary increase the dose to 30 mg. eradicationH. pylori: 30 mg twice daily for 7 days in combination with antimicrobial therapy (amoxicillin 1000 mg twice daily and Clarithromycin 250-500 mg twice daily or clarithromycin 250 mg twice daily and Metronidazole 400-500 mg 2 times per day) hours). Treatment of benign gastric and duodenal ulceration in patients requiring constant NSAID treatment: 30 mg once daily for 4 weeks, if necessary continue for another 4 weeks; in patients with ulcerations difficult to treat or the risk of ulcerations, treatment should probably be continued for a long time and / or higher doses. Prevention of gastric and duodenal ulcers associated with NSAID treatment in patients at risk who require continuous NSAID treatment: 15 mg once a day, if necessary, increase the dose to 30 mg. Gastroesophageal reflux disease with symptoms: 15-30 mg per day, individual dosage selection should be considered. Zollinger-Ellison syndrome: individually, 60-180 mg per day, there is no prescribed maximum period of use of the drug, a daily dose of more than 120 mg should be given in 2 divided doses. In patients with moderate or severe liver disease, it is recommended to reduce the daily dose by half. Do not exceed 30 mg daily in elderly patients. Capsules should be taken whole in the morning (in case of eradicationH. pylori morning and evening) 30 minutes before a meal. Kaps. it can also be emptied, but its contents should not be chewed or crushed.